Tag: stage

Global Data Center UPS Market to grow from USD 5.5 billion in 2023 to USD 9.2 billion by 2030 as AI workloads, hyperscale cloud...

Scout Clean Energy celebrated the opening of its Ottawa office and the launch of construction on its Trail Road Battery Energy Storage System.

FDA clearance enables initiation of first-in-human Phase 1/2a clinical trial evaluating LM-LLO-TT, Matter Bio's attenuated Listeria monocytogenes-based immunotherapy candidate.SAN FRANCISCO, June 10, 2026 /PRNewswire/ --...

The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies.BOSTON...

USMNT Legend Brian McBride named “Honorary Mayor of Believe, USA” at opening of the Truly Believe Bar ahead of this summer’s tournament

USMNT Legend Brian McBride named “Honorary Mayor of Believe, USA” at opening of the Truly Believe Bar ahead of this summer’s tournament

Selected as the lead organization for a major government-backed initiative to accelerate commercialization of bio-based 3-HP through pilot-scale investments.Establishing an integrated R&D value chain...

NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

As global football's ultimate spectacle kicks off on June 12, the 'Aleph Arena' digital hub will host one match per day and over 5,000...

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapyKey PointsSuperior PK: Subcutaneous administration of ADCs...

The dancewear market is witnessing steady adoption across dance academies, professional dance companies, fitness centers, educational institutions, performance arts organizations, and individual consumers due...

A new cellulose-based material platform developed in Finland responds to tightening regulatory requirements and industry pressure to both replace and reduce plastic in packaging,...

NUREMBERG, Germany, June 10, 2026 /PRNewswire/ -- NOVOSENSE Microelectronics (SSE: 688052 | HKEX: 02676) is exhibiting at PCIM Europe 2026, held from June 9...

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.